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Summary
All organisms are exposed constantly to a variety of infectious and injurious
stimuli. These induce inflammatory responses tailored to the threat posed.
While the innate immune system is the front line of response to each
stimulant, it has been considered traditionally to lack memory, acting in a
generic fashion until the adaptive immune arm can take over. This outmoded
simplification of the roles of innate and acquired arms of the immune system
has been challenged by evidence of myeloid cells altering their response to
subsequent encounters based on earlier exposure. This concept of ‘innate
immune memory’ has been known for nearly a century, and is accepted
among myeloid biologists. In recent years other innate immune cells, such as
natural killer cells, have been shown to display memory, suggesting that
innate immune memory is a trait common to several cell types. During the
last 30 years, evidence has slowly accumulated in favour of not only
haematopoietic cells, but also stromal cells, being imbued with memory
following inflammatory episodes. A recent publication showing this also to be
true in epithelial cells suggests innate immune memory to be widespread, if
under-appreciated, in non-haematopoietic cells. In this review, we will
examine the evidence supporting the existence of innate immune memory in
stromal cells. We will also discuss the ramifications of memory in long-lived
tissue-resident cells. Finally, we will pose questions we feel to be important in
the understanding of these forgotten cells in the field of innate memory.
Keywords: endothelial cell, fibroblast, inflammation, innate immune mem-
ory, stromal memory
Introduction
In an immune setting, the term ‘memory’ evokes vaccines,
memory T cells and the antibody response. Memory in
mammals is not, however, solely the remit of lymphocytes.
The field of immunology is changing, and evidence in both
arms of the immune system is breaking down old concepts
of innate and adaptive roles.
Inflammatory memory is an ancient characteristic of
innate immune cells. Vertebrate–invertebrate divergence
preceded the appearance of adaptive immunity, and yet
evidence in invertebrates as disparate as meal worm beetles
and shrimp, Drosophila and lower metazoans all points
towards inflammatory responses altered by prior exposure
to infectious agents (reviewed in [1]).
Innate immune memory in mammals was first observed
during the early 20th century. The bacillus Calmette–
Guerin (BCG) vaccine was found to save more children
than died of tuberculosis, indicating an off-target effect [2].
This work has progressed over decades to illustrate innate
memory in a range of experiments studying mammalian
defence against secondary pathogens. Crucially, studies in
severe combined immune deficiency (SCID) mice have
shown the BCG off-target protection to be driven by
innate – not adaptive – memory [3,4]. Such research has
focused mainly on myeloid cells, with other haematopoietic
cell types also attributed to innate memory in recent years
(reviewed in [5] and [6]).
Despite the abundance of research on innate memory,
stroma is still largely overlooked when considering repeat
challenges in immune or inflammatory episodes. Indeed,
the recent discovery of epithelial innate memory [7]
prompted a Nature news and views article, which stated:
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‘This is the first identification of inflammatory memory in
a non-immune cell’ [8]. It is clear that stromal memory is
not well-known or appreciated.
Given the recent resurgence of interest in stromal mem-
ory responses, and the latest observations showing that
haematopoietic, epithelial and stromal cell types all alter
their responses based on previous insults, we believe it is
time to discuss the field of stromal innate memory. In this
review, we will collate three decades of stromal memory
research, discuss its strengths and unanswered questions
and suggest key avenues of enquiry. Innate memory is
proving ever more important to our understanding of
inflammation biology, and it is time that stroma, the for-
gotten cells of the memory field, were remembered.
Because some of the important terms in this review may
be subject to different interpretations, we will begin with
some definitions. The ‘stroma’ comprises ubiquitous struc-
tural cells, providing extracellular matrix (ECM) and sup-
port functions in every organ. In this review we take
‘stromal cells’ to exclude cells of haematopoietic origin; for
example, tissue-resident macrophages. Macrophages and
other myeloid cells are discussed below merely by way of
introduction to the concept of memory. To our knowledge,
the vast majority of the research relevant to stromal mem-
ory has been performed on fibroblasts and endothelial cells.
We therefore focus on these cells, but we consider it very
likely that memory also exists in other stromal cell types.
We define ‘memory’ as a state of altered responsiveness
that does not depend upon the continued presence of the
stimulus by which it is evoked. A key characteristic of this
form of memory is that it outlasts the primary signalling
response of the cell. In the experiments discussed below
memory lasts from days to weeks, or even longer. There
will clearly be some overlap between memory and differen-
tiation, for example in a few experimental designs dis-
cussed below, where stromal cells are exposed to persistent
inflammatory stimulation rather than being stimulated,
rested, then stimulated again. As far as this review is con-
cerned, we define ‘inflammatory memory’ as a change in
the capacity of stromal cells to respond to inflammatory
stimuli, as opposed to an inflammation-induced change in
steady-state gene expression.
Stroma in inflammation
During the last three decades, our understanding and
appreciation of the roles played by stromal cells in healthy
and pathological inflammation has increased exponentially.
Two well-studied stromal cells [endothelial cells (EC) and
fibroblasts] are described below.
EC line the blood and lymph vessels, and thus have an
important role in inflammation. Both host and foreign cells
must interact with EC in order to extravasate into tissue.
Their release of chemokines recruits leucocytes to a site of
infection or injury, and their expression of adhesion
molecules facilitates adhesion, rolling and diapedesis of cir-
culating cells (reviewed in [9]).
Fibroblasts are a major source of ECM and play organ-
specific roles, such as lubricin production in the joint and
lymphocyte support in lymphoid organs. They act as
immune sentinels, with some capacity for phagocytosis
[10] and antigen presentation [11]. They also release che-
mokines to recruit leucocytes and cytokines to modulate
the nearby EC [12]. The fibroblast influence on EC adhe-
sion molecule expression has profound effects on leucocyte
extravasation. In healthy inflammation fibroblasts limit
extravasation through EC, while fibroblasts from inflamed
joints promote increase leucocyte extravasation [13,14].
Once leucocytes extravasate into tissue, fibroblasts influ-
ence their behaviour via the regulation of survival, activa-
tion, differentiation and retention [15,16]. It is therefore
not surprising that pathologically altered fibroblasts are
integral to several chronic inflammatory diseases. The roles
of stromal cells in inflammation are illustrated briefly in
Fig. 1. Due to the number of roles played, understanding
how these cells alter their behaviour after an initial inflam-
matory episode could be crucial to our understanding of
human pathology.
Myeloid innate memory
Monocyte/macrophages are innate cells of the myeloid line-
age, which act as immune sentinels, phagocytes of patho-
gens and cellular debris and as professional antigen
presenters. In this sense, they are often recognized as the
link between innate and adaptive immunity. This is also
true in a temporal sense, as many studies have found that
monocytes infiltrate tissue after neutrophils but before
lymphocytes [17,18]. Others also found that the phagocy-
tosis of apoptotic neutrophils by macrophages (known as
efferocytosis) is a key point in progressing from the acute
to the adaptive phase of inflammation (reviewed by [19]).
As an intermediary between the two arms of our immune
system it is perhaps not surprising that, of all innate cells,
macrophages should have memory. This may take either
positive or negative forms, in that the response to a second
challenge may be either enhanced or diminished by memory
of a prior challenge. Both short- and long-term forms of
myeloid cell memory have been described. Long-lived mye-
loid cell memory that underpins the beneficial off-target
effects of vaccines such as BCG has been coined ‘trained
immunity’ by Netea and colleagues [1]. This phenomenon is
exhibited only after the cells have been educated by an initial
infection, lasts for several weeks or even months after the
initial infection, and induces an augmented inflammatory
response to second infection. The long-term alteration is
driven by epigenetic modifications, which are described in
more detail later. Trained immunity has been studied in a
wide range of primary and secondary challenges, and partic-
ular attention has been paid to the BCG vaccine and fungal
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products (b glucan) or organisms (Candida albicans) as pro-
viding wide-scale protection against a range of secondary
agents. This protection takes the form of lower mortality
rates and better pathogen clearance [4].
The other form of memory is a transient reduction of
the inflammatory response. In 1947 bacterial substances
were found to have diminishing pyrogenic effects in rabbits
receiving successive doses [20]. In 1965, this was furthered
by research showing that rabbits could be saved from death
by a lethal dose of liposaccharide (LPS) if they had
previously received a sublethal dose [21]. This phenom-
enon was termed ‘endotoxin tolerance’, and was attributed
to macrophages some time later. While tolerance implies
no effect of endotoxin on the macrophage, this is an over-
simplification. It is true that successive doses of endotoxin
abrogate the expression of proinflammatory mediators but,
contrastingly, increase expression of genes related to phag-
ocytosis [22]. This results in a phenotype which avoids tis-
sue damage while still facilitating removal of infectious
agents. It is therefore important to distinguish it from
‘immune paralysis’: the state of disorganized immune
response seen after trauma or burns, and a contributing
factor to mortality in sepsis patients [23]. Endotoxin toler-
ance is therefore a sophisticated state of altered responsive-
ness, rather than simply an ‘off switch’ for macrophages.
Fibroblast inflammatory memory
The study of fibroblast memory goes back to 1992 [24].
Early papers arose from discoveries pertaining to modula-
tion of interleukin (IL)-8 expression by interferon (IFN).
After the discovery that IFN-b or -g would reduce tumour
necrosis factor (TNF)-a-induced IL-8 expression [25], a
series of publications examined the effect of IFN on endog-
enous or exogenous induction of IL-8, including the conse-
quences of challenging fibroblasts with one stimulus and
then another [24,26–28]. Thus, the field was born.
The earlier years of the new millennium saw no new pub-
lications on the subject, and it appeared forgotten. In the
interim, appreciation of fibroblast involvement in chronic
Fig. 1. Roles of stromal cells in inflammation. Illustration of the functions stromal cells use to influence the fate of an inflammatory episode.
Secreted and presented mediators are illustrated, as are as key organizational roles.
T. Crowley et al.
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inflammatory diseases was continuing to grow. With the
greater understanding of stromal epigenetic alterations
resulting in long-term increases or decreases of chromatin
accessibility, authors began to suggest that a ‘fibroblast
inflammatory memory’ may be involved in the perpetuation
[29,30] or re-ignition [31], of inflammatory conditions.
At the same time, the primary publications on fibroblast
memory were re-emerging. In 2009 gingival fibroblasts
were shown to maintain their inflammatory response to re-
challenge with LPS, whereas macrophages became refrac-
tory [32]. In 2011, however, gingival fibroblasts were
shown to be capable of tolerance, but in a gene-specific
fashion [33]. A recent spate of publications [34–38] has
advanced our understanding further. Sohn et al. displayed
inflammatory memory of T cell chemoattractants in
fibroblast-like synoviocytes (FLS) derived from patients
with rheumatoid arthritis (RA) [39]. Our own work built
upon these findings by displaying positive memory to be
shared by FLS from both inflamed and non-inflamed joints
[37]. While both papers showed gene-specificity of mem-
ory in response to endogenous stimuli, the latter also dis-
played trophism, showing that FLS had memory while
dermal fibroblasts did not. These findings suggest that
inflammatory memory can be a property of the site of ori-
gin of fibroblasts rather than disease state.
Recently, Klein et al. also demonstrated the tropism of
fibroblast memory and its gene-specificity [38]. Repeat
challenges with LPS induced a refractory state seen only in
fibroblasts of certain sites, and only in genes linked to the
anti-viral response. Dakin et al. showed that tendon fibro-
blasts from chronic tendinopathy patients mounted stron-
ger inflammatory responses in vitro than those of healthy
tendons, thus demonstrating the longevity of innate
immune memory in fibroblasts [35,36]. They also discov-
ered that while intracellular signalling diminished over
time after removal of stimulus, surface markers of fibro-
blast activation such as podoplanin (PDPN) and vascular
adhesion molecule-1 (VCAM-1) were maintained at high
levels. This suggests that memory in stromal cells does not
necessarily manifest as continued inflammatory secretion,
but rather as an altered state of readiness with increased
activation receptors [36] and altered chromatin accessibil-
ity [38,39]. The altered expression of some fibroblast cell
surface markers at sites of chronic inflammation could be
interpreted as a differentiation phenomenon. Alternatively,
it could reflect expansion of a fibroblast subpopulation that
responds differently to inflammatory challenge. These
interpretations cannot be resolved without deeper under-
standing of the molecular mechanisms involved.
Endothelial cell inflammatory memory
Research into the concept of endothelial cell memory is
newer than that of fibroblast memory, but a range of chal-
lenges have been examined. This field dates at least to 2002
[40], and publications are increasing in frequency. As seen in
fibroblast memory, some authors have not found an altered
response to second challenge [41], while others have shown
both positive and negative memory responses indicative of a
complex interplay of stimuli and cellular pathways. The
examination of cross-stimulation (initial and secondary
stimuli inducing different pathways) has led to the conclu-
sion that some mechanisms of innate memory are shared
with the myeloid lineage [42], but not all observations
match, suggesting cell- and stimulus-specific pathways.
The anatomical site of origin and inflammatory stimulus
have been shown to dictate EC memory responses, and the
vessel architecture has also been demonstrated as impor-
tant. Shear stress (pressure exerted by blood flow on the
vessel walls) is higher in straight vessel sections than arches
or junctions. Work from the Evans laboratory has shown
that EC under low shear stress have constitutively active c-
Jun N-terminal kinase (JNK) [43], which is suppressed by
dual specificity phosphatase-1 (DUSP-1) in areas of high
shear stress [44]. This high level of JNK activity correlates
with VCAM-1 expression and thus the ability to facilitate
leucocyte adhesion. The authors described JNK as ‘pri-
ming’ EC for inflammation, and pointed out that primed
areas were atheroprone, while areas with high shear stress
and suppressed JNK activity were atheroresistant.
Studies have confirmed the relevance of EC memory in
both infectious and non-infectious inflammatory contexts.
Prior infection by Schistosoma mansoni increases leucocyte
adherence through the endothelial layer [45]. Others have
shown that EC exposed to circulating contributors to ath-
erosclerosis have augmented inflammatory responses to
subsequent challenges by exogenous or endogenous stimuli
[40,46]. In the examples above, altered EC responses were
driven by persistent exposure to inflammatory stimuli.
Whether such changes should be considered as memory or
differentiation is arguably a question of semantics.
In 2008, Zemani et al. found that EC progenitors per-
formed better as therapeutic cells in models of ischaemic
injury if they were primed ex vivo with C-X-C motif chemo-
kine ligand 12 (CXCL12) before donation [47]. Similarly, in
2016 Stark et al. found the endotoxin tolerance seen in EC
could be manipulated. An initial challenge with LPS induced
an inflammatory response, which was followed by non-
responsiveness to subsequent LPS challenges. If, however,
monophosphoryl lipid A (MPLA) was used as the initial stim-
ulus, the non-responsiveness to LPS was achieved without an
initial inflammatory event [48]. This suggests that EC mem-
ory may be amenable to therapeutic manipulation. Thus,
there is an obvious need to understand endothelial memory
at basic science and clinical levels.
Mechanisms underpinning innate memory
The mechanisms behind innate memory have been investi-
gated intensively in the myeloid lineage. The effects of Toll-
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like receptor (TLR)-4 signalling in particular have received
most attention, and have been reviewed comprehensively
[49]. For this review, it suffices to say that TLR-4 signals
through the myeloid-differentiation primary response pro-
tein 88 (MyD88) and Toll/IL-1R (TIR)-domain-containing
adapter-inducing IFN-b (TRIF) pathways. MyD88 induces
proinflammatory cytokine expression through pathways
such as that of nuclear factor kappa B (NF-jB). TRIF indu-
ces the interferon response and thus the production of IFN
response factors (IRF) and anti-viral effectors. These path-
ways are well established and reviewed by [50].
Negative feedback signalling
The proinflammatory TLR-4 response is, as with all healthy
inflammatory episodes, curtailed by in built feedback loops
[51,52]. Both the MyD88 and TRIF pathways induce the
expression of negative regulators. These may inhibit TLR-4
signalling at levels distal, intermediate or proximal to gene
expression. IL-1 receptor-associated kinase (IRAK) M and
A20, for example, inhibit, respectively, the release of IRAKs
and TNF receptor-associated factor (TRAF)6 from MyD88,
and the actions of TRAF6 and TRIF [53,54]. Conversely,
SH-2 containing inositol 5’ polyphosphatase (SHIP) 1
inhibits inhibitor of jB kinase (IKK) activity downstream
of MyD88 and IRF3 downstream of TRIF [55]. Finally, the
non-canonical NF-jB p50 homodimer can inhibit canoni-
cal NF-jB binding to promoters, presumably by steric hin-
drance [56].
Two studies of fibroblasts are useful to note here. The
first is that of Lee et al. [57], who showed that rheumatoid
arthritis RA-derived FLS maintained an inflammatory
response to TNF-a up to at least 4 days after initial chal-
lenge. The authors also displayed FLS expression of several
of the negative regulators to be negligible compared to
expression in macrophages. The second is that of Ara et al.
[32], who found that neither Escherichia coli LPS nor Por-
phyromonas gingivalis LPS (TLR-4 and TLR-2 agonists,
respectively) could induce tolerance in gingival fibroblasts.
They also showed that human gingival fibroblasts lack
expression of classic negative regulators. During myeloid
endotoxin tolerance, negative regulators are up-regulated,
leading to disrupted signalling through both pathways.
While the above fibroblast studies showed a deficiency in
negative regulators, neither showed explicitly that this was
the reason for propagation of the inflammatory response.
Future studies are necessary to link these observations with
alterations in memory responses, as has been confirmed in
myeloid cells [58].
IFNs
IFNs are induced in response to infectious agents, and also
in response to tumour cells and proinflammatory cyto-
kines. Their role in innate memory appears multi-faceted.
IFN-g, for example, can rescue endotoxin tolerant
macrophages from their refractory state by opening con-
densed chromatin [59]. Conversely, IFN-b can induce tol-
erance of a subset of genes in fibroblasts [24,33]. Even in
studies of the same cell type (i.e. fibroblasts), IFNs were
shown to have both inhibiting [24,26,28] and augmenting
[26,28] roles. This disparity was not due to the IFN, but
rather to the timing of its administration. Sohn and col-
leagues found that IFN-a, -b and -g could all induce aug-
mented responses from TNF-a-primed FLS [34]. This not
only confirms that different IFNs may have redundant roles
in innate immune memory, but also provides evidence that
they may act as the initial or secondary challenge.
Koch et al. developed a theory based on cross-priming
EC with TLR agonists [42]. They suggested that initial
stimulation induced an increase in IRF-7 accumulation,
facilitating a greater response to subsequent challenges.
Such a theory may be supported by the finding that FLS
have a TNF-a-induced IFN-b autocrine feedback loop
which increases chemokine release [60]. If both mecha-
nisms were conserved across FLS and EC, one could envis-
age the initial stimulation providing a large IRF pool,
leading to a greater cellular response to autocrine IFN feed-
back in the second response. This model relies upon unit-
ing mechanisms from different cell types. Even among
fibroblasts of different origins this may be inappropriate, as
synovial fibroblasts release IFN-b [60], while those from
the gingiva do not express it [33]. The effects of trophism,
and of different experimental designs with different cell
types, stimuli and readouts, means that three decades of
research have yet to provide a clear model for the role of
interferons in stromal memory.
NF-jB
The NF-jB pathway is well known for its involvement in
the expression of proinflammatory genes. In macrophage
endotoxin tolerance, the canonical NF-jB pathway is
refractory. Its inhibition is induced by the increase in
inhibitory p50 homodimers at the loci of proinflammatory
genes [56]. There is also increased repression of the IKK
complex. Due to this, the abundance of Ij-Ba is higher in
tolerized than naive cells [61], and it has also been reported
to replenish its cytoplasmic pool faster in the second chal-
lenge compared to the first [58,59].
Studies have shown that repeated TLR-4 engagement
leads to repression of the NF-jB pathway in endothelial
cells [42,46]. This included decreased activation of the IKK
complex and concomitant reduction in NF-jB-dependent
cytokines. In direct contradiction, Wang et al. found that
the second challenge with TLR-4 agonist increased EC
cytokine production, and this correlated with increased
NF-jB pathway activity [41]. Both studies used human
umbilical vein ECs and E. coli LPS for their experiments, so
the explanation for the disparity is unclear. What is clear,
however, is that the action of the NF-jB pathway during
T. Crowley et al.
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the memory response correlated with the increase or
decrease of inflammatory mediators elicited by the second
challenge. There is also evidence for NF-jB-dependent
altered responses in fibroblast memory. In fibroblasts
stimulated with TNF-a for 24 h then rested for 24 h, both
NF-jB activity and IL-6 expression subsided to basal levels
during the rest period. Restimulation of the rested cells
caused more prolonged NF-jB activation, and increased
expression of IL-6 that was dependent upon NF-jB. At
least in this case, the inflammatory memory of fibroblasts
is not simply persistence of cell activation, but reflects pri-
ming of the NF-jB signalling pathway for an augmented
response [37]. The Kalliolias group showed that TNF-a-
treated RA FLS continued to express inflammatory media-
tors for up to 4 days in a manner dependent upon sus-
tained NF-jB activity [56]. They showed later that NF-jB
was also required for priming of these TNF-a-exposed cells
to respond more strongly to IFN stimulation [34].
Chromatin access and epigenetics
Epigenetic modification is generally regarded as key to the
innate memory seen in macrophages. Trained immunity
induces an augmented response to second challenge weeks
or even months after the initial infection. Changes on such
a time-scale are likely to be epigenetic and, indeed, evi-
dence abounds for such a theory. Permissive modifications
have been described by several groups [4,62].
Endotoxin tolerance is a memory response of a much
more short-term nature. While previous examples show
evidence for upstream mediators, the study of epigenetics
has transferred well to the tolerance field. Examples of this
include the length of endotoxin tolerance in macrophages,
which has been shown to be from 24–48 to 5 days in dura-
tion [22,63]. Medzhitov and colleagues showed that macro-
phage endotoxin tolerance was induced by gene-specific
transcriptional repression, occurring at the level of chroma-
tin condensation [22]. This is in accordance with findings
of other groups [59,64].
The chromatin landscape in stromal memory is receiv-
ing increasing attention. When EC were primed with TLR-
3 agonist, the CXCL10 induction by subsequent TLR-4
agonist was augmented and this was reduced by inhibiting
histone deacetylases [42]. This suggests that the induction
of chromatin opening is part of the augmented stromal
memory response. Studies in fibroblasts have also sug-
gested epigenetic changes [29].
More explicit evidence came from Sohn et al., who
showed that chronic exposure of RA FLS to TNF-a led to
decreased histone H4 levels, increased H4 acetylation and
increased NF-jB and PolII occupancy at the promoter of
genes which could be augmented subsequently upon
rechallenge. Blocking TNF-a with infliximab for 24 h
before the rechallenge did not reduce the augmented
response, suggesting that a permissive state had already
been established. This may correlate well with the latent
enhancers found to have prolonged transcription factor
occupancy in trained macrophages [65]. The recent publi-
cation by Klein et al. also showed the chromatin landscape
to determine which genes became tolerant in macrophages
and synovial fibroblasts derived from different anatomical
sites [38]. Genes that could not be tolerized had similar
epigenetic markers in the first and second responses to
LPS. Those that were refractory in the second challenge dis-
played decreases in histone markers associated with accessi-
bility, thus showing that epigenetic silencing contributes to
the control of which genes display innate immune memory
profiles.
A generic example of the signalling events known to
occur in stromal cells undergoing tolerance or augmented
responses is illustrated in Fig. 2.
Role of stromal memory in infection and chronic
inflammatory disease
We are well aware of the deleterious nature of flawed adapt-
ive immunology. The number and variety of autoantibod-
ies contributing to a large range of autoimmune diseases
displays the danger of what is ostensibly beneficial in
infection.
Endotoxin tolerance reduces the inflammatory response
of myeloid cells to infectious triggers and thus preserves
the host’s life. Very low doses of LPS, however, do not
induce tolerance, but rather a chronically inflamed state
[66]. In this sense, it is possible that low-dose stimulants
actually prime the host to augmented second responses.
The augmented second response to infection is well
reported in vivo and in macrophages [5]. The ‘red alert’ of
innate immune cells may induce heightened responses to
infectious triggers, but also similarly to endogenous
factors.
The concept of endogenous factors priming the response
to damage-associated molecular patterns (DAMPs) is
established in the stromal memory field. Homocysteine
(HCy) is a circulating amino acid used as a clinical marker
for atherosclerosis risk. It has been shown to synergize with
TNF-a to induce stronger activation of EC [40]. The
authors hypothesized that HCy may prime EC for aug-
mented responses to damage. While not tested explicitly in
the publication, this was proved by another group, who
showed that concentrations of HCy only slightly higher
than normal physiological range could prime aortic EC to
an augmented inflammatory response to LPS or thrombin
[an exogenous pathogen-associated molecular pattern
(PAMP) and an endogenous DAMP, respectively] [48].
The role of EC as inflammatory contributors to athero-
sclerosis is well established [44,67], and the role of myeloid
trained immunity in the disease is also gaining attention
(reviewed in [68,69]. These publications and others
[34,37,40,48,70] acknowledge the dangers of innate
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memory facilitating over-aggressive inflammatory
responses based on priming by endogenous mediators.
DAMPs and other host products inducing this high alert
state may lead to chronic inflammatory conditions because
they will tend to favour sustained inflammatory responses
rather than resolution of inflammation. In some of these
examples, whether augmented inflammatory responses are
dependent upon continued presence of the ‘priming’ agent
remains to be tested formally. The effects of stromal mem-
ory responses to endogenous ligands is shown in Fig. 3.
Research into fibroblast memory also suggests a patho-
logical role. Our own research into non-inflamed and RA
synovial fibroblasts suggests that the augmented proinflam-
matory response is inherent to the joint [37]. This may
help to explain the capacity of antibodies against widely
expressed antigens to drive joint inflammation. Recent
research from Oxford University suggested that chronic
tendinopathy was due to an initial (and supposedly
resolved) insult, which led nonetheless to fibroblasts
acquiring a fibrotic and hyper-responsive phenotype
[35,36]. As remarked above, the altered fibroblast pheno-
type may be explained in part by differentiation or expan-
sion of a fibroblast subpopulation.
Two publications have shown healthy skin fibroblasts to
be incapable of the augmented response [32,37]. In con-
trast, unpublished work from our department suggests skin
fibroblasts from psoriatic plaques pathologically acquire
augmented inflammatory responses to rechallenge (i.e.
positive memory; manuscript in preparation). This concept
of fibroblasts in a chronically inflamed setting acquiring
inflammatory memory appears to be supported by fibro-
blasts from other tissues we have studied, and particularly
gingival fibroblasts. These cells have inflammatory memory
when isolated from periodontitis patients (manuscript in
preparation), but not from healthy patients [32,33].
The concept of changes in fibroblasts contributing to
chronic joint inflammation is well established [71,72]. The
perturbation of surface markers leading to site-specific leu-
cocyte recruitment (the stromal postcode) in chronic
inflammation was reviewed more than 10 years ago [73].
Fig. 2. Mechanistic responses to first and second response to stimulation. Simplified stromal cell response to initial response (left), and abrogated
(centre) or augmented (right) memory response to second challenge.
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Fig. 3. Progression of chronic inflammation through stromal memory. The increasingly inflamed stromal microenvironment during challenge
with endogenous mediators is illustrated. (a) The stromal compartment at rest. (b) The inflammatory response of stromal cells leads to an
inflamed microenvironment, but negative regulatory and pro-resolution pathways ensure timely resolution. (c) Continued challenges lead to
increased endothelial cell adhesion molecule expression and chemokine expression. Fibroblasts also increase cytokine and chemokine release,
inducing inflammatory responses from both endothelial cells and leukocytes. Magnified image illustrates the changes at the chromatin level.
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The idea that fibroblast memory may be inherent in some
sites, but gained aberrantly in others, is therefore not an
unusual notion.
The clinical significance of stromal memory
A host of publications have recognized the modulating influ-
ence of prior inflammatory events [68,74–77]. This will
obviously due be partly to the adaptive immune response,
but as this review has shown, the effect on other cell types,
and so the tissue or even organism as a whole, are not to be
dismissed. Didierlaurent and colleagues discussed the effects
of repeat lung infection [74], while Dakin et al. hypothesized
[31] and later confirmed [36] that an acute injury event may
prepare tendons for chronic tendinopathy and fibrosis upon
a second insult. Such concepts show a clear clinical relevance
to repeat challenge of innate cells.
Vaccines have proved beyond doubt the clinical benefit
of harnessing adaptive immunity. In the same sense, mac-
rophage innate memory is host-protective in various infec-
tious scenarios. Trained immunity protects the host by
putting macrophages (and NK cells) on high alert for sub-
sequent infections. Conversely, endotoxin tolerance reduces
inflammatory secretions but maintains phagocytic function
to defend the host from cytokine storm.
These two sides of innate memory present an attractive
therapeutic opportunity. Mihai and van der Meer have
expounded the theory of an ‘innate vaccine’ in order to
harness trained immunity [5]. This has, in a way, already
been invented in the form of the BCG vaccine mentioned
earlier, and trials to explicitly test its validity as an infection
non-specific vaccine have been conducted [78]. Impor-
tantly, the innate vaccine may also be used to defend the
host against non-infectious conditions such as autoinflam-
matory and allergic diseases [79]. Harnessing the short-
term memory of macrophages has yet to come to fruition,
and the similar (although distinct) ‘immune paralysis’ of
sepsis patients continues to play a deleterious role [80].
Although the field of stromal memory is still relatively
understudied, clinical relevance has already been evidenced.
As stated earlier, ex-vivo challenging of EC progenitors
with CXCL12 induced greater homing to activated EC and
greater tube formation [45]. The authors suggested that
this priming dose would improve efficiency of cell therapy
following ischaemic disease. In 2016, Stark et al. showed
that in-vitro endotoxin tolerance could be achieved in EC
by stimulating with MPLA rather than LPS [46]. This
would render EC refractory to infectious triggers of inflam-
matory responses without the inflammation induced by
the first LPS challenge. Such a mechanism would be of ben-
efit in the setting of chronic inflammatory disease, wherein
the EC themselves, or the underlying inflamed tissue,
induce pathological recruitment to, and extravasation
through, the endothelium. A possible example is periodon-
titis, in which microbiota and host immune responses
conspire to produce the most common chronic inflamma-
tory disease in the world [81]. Zaric et al. showed that
induction of tolerance could be achieved in gingival fibro-
blasts if IFN-b was provided [33]. Such a reduction in
inflammatory response may provide a break in the inflam-
matory cycle and facilitate the induction of resolution.
While targeting circulating cells is always easier than a spe-
cific resident population, this latter option is progressing,
with improved targeted drug delivery making the targeting
of tissue-resident stromal cells a real possibility [82].
Future questions
The increased interest in this field during the last few years
has shed light upon several facets of stromal memory. It is,
however, still a field in its in infancy. The aspects we feel to
be most pressing are as follows.
Although in-vitro challenge and rechallenge experiments
can shed light upon mechanisms of stromal cell memory,
they model the situation poorly in vivo. Ground-breaking
experiments by M€uller-Ladner and colleagues demonstrated
that RA synovial fibroblasts could be maintained in tissue
culture without losing their erosive properties in an in-vivo
model of cartilage degradation [83]. It has been argued [70]
that prolonged exposure of synovial fibroblasts to an inflam-
matory environment engenders lasting epigenetic changes,
for example at the level of DNA methylation or micro-RNA
expression, which strengthen responses to proinflammatory
stimuli. However, the acquisition of the aggressive pheno-
type is not yet well understood. We need better integration
between in-vitro approaches and elegant in-vivo experiments
of this kind. This may require the use of irradiated chimeras,
or even models deficient in immune cells.
The role played by metabolism is currently not known.
The field of immunometabolism has expanded rapidly in
recent years, and inflammatory triggers are known to alter
metabolic processes in both haematopoietic and stromal
cells [84]. Further, chronic inflammatory diseases are
known to correlate with altered cellular metabolic profiles
[85,86]. A precedent for the involvement of metabolism in
innate memory already exists, as the Netea group have
shown that monocyte training by prior challenge involved
a shift towards glycolytic metabolism both in vitro and in
vivo [62,87]. Given the link these papers made between
innate memory, epigenetics and metabolism, the ability to
understand and manipulate stromal memory could depend
upon a greater appreciation of this axis.
As described earlier, there is disparity between in-vitro
repeat stimulation and real-world inflammatory pressures.
Therefore, although some features of inflammatory mem-
ory of stromal cells have been described, the adaptive value
of the phenomenon remains unclear. Its gene-specific
nature suggests that it may be a mechanism to fine-tune
the recruitment of leucocytes during the evolution of an
inflammatory episode, or to modify inflammation-induced
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recruitment to sites that have previously experienced
inflammation.
The contribution to chronic inflammatory disease is also
yet to be defined clearly. Why is it that stromal memory
differs according to site of origin [37,38,42,46]? Why may
it also differ between cells from healthy and chronically
inflamed tissue? Stromal positional identity is long estab-
lished, and shows at both epigenetic [88,89] and functional
levels [13,90,91]. If some sites (such as the joint) are more
inclined to stromal memory, does this contribute to the
likelihood of chronic inflammation in that site? Such
knowledge could provide a powerful new prophylactic tool
in those with susceptibility alleles.
Finally, if cells from chronically inflamed tissue have
memory, is it part of the cause for inflammation or is it
acquired in the course of inflammation? If the former, we
have a new susceptibility marker which may be more tissue
and disease-specific than most of the genome-wide associa-
tion study (GWAS) hits (which are often shared among
many diseases). If the latter, this provides a new therapeutic
target which could be applied to any chronic inflammatory
disease where memory is acquired. Such a therapeutic
would have the dual benefit of targeting more than one dis-
ease, and of leaving the patient immunocompetent.
Conclusions
Innate memory in humans was recognized nearly a century
ago, and for years was seen as the prerogative of myeloid
cells. Innate memory, whether in the guise of endotoxin
tolerance or trained immunity, is host protective. The for-
mer protects from tissue damage and cytokine storm, while
the latter provides a generic augmented response to future
infection. Recently non-myeloid lineages were also recog-
nized to exhibit memory, and stromal memory is starting
to receive the attention it deserves.
The roles of stromal cells in inflammation are manifold,
and crucial in inflammatory responses to both infection and
injury. The field of stromal memory is still in its infancy,
and yet already promises to reshape our understanding of
stromal cells’ roles in inflammatory episodes. Of the evi-
dence presented herein, some suggest that stromal memory
may be adaptive, and others deleterious. Some suggest a
double-edged sword, protecting against infection at the risk
of autoinflammatory conditions. The data are varied, but
the consensus in the field is that this under-investigated
mechanism will undoubtedly influence the nature, magni-
tude and duration of inflammatory episodes. Stromal mem-
ory, therefore, is well worth remembering.
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